Office of Technology Transfer – University of Michigan

Novel Acinetobacter baumannii biofilm inhibitors

Technology #6671

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
David H. Sherman
Managed By
Ed Pagani
Assistant Director, Health Technologies 734-763-3558
Patent Protection
US Patent Pending

Acinetobacter baumannii are opportunistic pathogens that are frequently associated with hospital acquired infections. Multi-drug resistant strains are not uncommon and even pan-resistant strains have been identified. This antibiotic resistance appears to be mediated through the formation of biofilms. Biofilms are formed through a highly structured extracellular polymeric matrix which allows the bacteria to group together on a surface. When A. baumannii lose the ability to form biofilms, they become susceptible towards antimicrobial agents.

Identification of Novel Biofilm Inhibitors

To identify inhibitors of A. baumannii biofilm formation, high-throughput screening was performed using a library of marine microbial derived natural product extracts. This lead to the identification of a metabolite, cahuitamycins, derived from Streptomyces gandocaensis. This class of compounds was demonstrated to inhibit biofilm formation in several in vitro assays.

Applications

  • Therapeutic for Acinetobacter baumannii infections
  • Antimicrobial agent for medical device sterilization

Advantages

  • There is a critical need to generate novel antimicrobial agents
  • May be used in combination with existing antibiotics for improved efficacy